ArticleProceedings of the National Academy of Sciences of the United States of America2016
Development of high-yield influenza B virus vaccine viruses.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Generation of an autophagy-targeting influenza A virus as live attenuated vaccine.Nature communications · 2026Article
- Genetic variation and vaccine match of influenza B virus in Riyadh, Saudi Arabia during three consecutive seasons, 2020-2023.Virus genes · 2026Article
- Development of broadly protective influenza B vaccines.NPJ vaccines · 2025Article
- Article
- The role of vaccines in the COVID-19 pandemic: what have we learned?Seminars in immunopathology · 2024Review
- Development of an Enhanced High-Yield Influenza Vaccine Backbone in Embryonated Chicken Eggs.Vaccines · 2023Article
- Generation of a high yield vaccine backbone for influenza B virus in embryonated chicken eggs.NPJ vaccines · 2023Article
- Substitutions near the HA receptor binding site explain the origin and major antigenic change of the B/Victoria and B/Yamagata lineages.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Generation of a live attenuated influenza A vaccine by proteolysis targeting.Nature biotechnology · 2022Article
- A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies.Nature communications · 2021Article
- Development and Effects of Influenza Antiviral Drugs.Molecules (Basel, Switzerland) · 2021Review
- Reverse genetics for influenza B viruses and recent advances in vaccine development.Current opinion in virology · 2020Review
- Review
- Current and future influenza vaccines.Nature medicine · 2019Review
- Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines.Antimicrobial resistance and infection control · 2019Article
- Efforts to Improve the Seasonal Influenza Vaccine.Vaccines · 2018Review
- Towards a universal influenza vaccine: different approaches for one goal.Virology journal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The burden of human infections with influenza A and B viruses is substantial, and the impact of influenza B virus infections can exceed that of influenza A virus infections in some seasons. Over the past few decades, viruses of two influenza B virus lineages (Victoria and Yamagata) have circulated in humans, and both lineages are now represented in influenza vaccines, as recommended by the World Health Organization. Influenza B virus vaccines for humans have been available for more than half a century, yet no systematic efforts have been undertaken to develop high-yield candidates. Therefore, we screened virus libraries possessing random mutations in the six "internal" influenza B viral RNA segments [i.e., those not encoding the major viral antigens, hemagglutinin (HA) and neuraminidase NA)] for mutants that confer efficient replication. Candidate viruses that supported high yield in cell culture were tested with the HA and NA genes of eight different viruses of the Victoria and Yamagata lineages. We identified combinations of mutations that increased the titers of candidate vaccine viruses in mammalian cells used for human influenza vaccine virus propagation and in embryonated chicken eggs, the most common propagation system for influenza viruses. These influenza B virus vaccine backbones can be used for improved vaccine virus production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.